PRTA icon

Prothena Corp

15.22 USD
-0.79
4.93%
At close Dec 20, 4:00 PM EST
After hours
15.10
-0.12
0.79%
1 day
-4.93%
5 days
18.72%
1 month
5.69%
3 months
-29.57%
6 months
-22.58%
Year to date
-60.51%
1 year
-58.78%
5 years
-3.97%
10 years
-26.26%
 

About: Prothena Corp PLC is a biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating rare neurodegenerative and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004).

Employees: 173

0
Funds holding %
of 6,809 funds
0
Analysts bullish %
of 3 analysts

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

46% more call options, than puts

Call options by funds: $3.01M | Put options by funds: $2.06M

7% more repeat investments, than reductions

Existing positions increased: 48 | Existing positions reduced: 45

5% more first-time investments, than exits

New positions opened: 23 | Existing positions closed: 22

1% more funds holding

Funds holding: 159 [Q2] → 160 (+1) [Q3]

0% more funds holding in top 10

Funds holding in top 10: 3 [Q2] → 3 (+0) [Q3]

1.31% less ownership

Funds ownership: 95.99% [Q2] → 94.67% (-1.31%) [Q3]

20% less capital invested

Capital invested by funds: $1.07B [Q2] → $855M (-$211M) [Q3]

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$22
45%
upside
Avg. target
$37
141%
upside
High target
$48
215%
upside

3 analyst ratings

positive
67%
neutral
33%
negative
0%
HC Wainwright & Co.
Andrew Fein
32% 1-year accuracy
105 / 327 met price target
215%upside
$48
Buy
Reiterated
20 Dec 2024
Chardan Capital
Rudy Li
33% 1-year accuracy
1 / 3 met price target
163%upside
$40
Buy
Initiated
20 Dec 2024
B of A Securities
Tazeen Ahmad
39% 1-year accuracy
11 / 28 met price target
45%upside
$22
Neutral
Maintained
19 Dec 2024

Financial journalist opinion

Based on 3 articles about PRTA published over the past 30 days

Positive
Investors Business Daily
2 days ago
Prothena Catapults, Flashing A Bullish Sign, On Promise In Parkinson's Disease
Prothena stock catapulted Thursday after the company's Roche-partnered Parkinson's treatment showed promise in a midstage study. The post Prothena Catapults, Flashing A Bullish Sign, On Promise In Parkinson's Disease appeared first on Investor's Business Daily.
Prothena Catapults, Flashing A Bullish Sign, On Promise In Parkinson's Disease
Neutral
Business Wire
2 days ago
Roche's Phase IIb Study of Prasinezumab Missed Primary Endpoint, But Suggests Possible Clinical Benefit in Early-Stage Parkinson's Disease
DUBLIN--(BUSINESS WIRE)---- $PRTA #prothena--Prothena today announced results from PADOVA study conducted by partner Roche investigating prasinezumab in early-stage Parkinson's disease.
Roche's Phase IIb Study of Prasinezumab Missed Primary Endpoint, But Suggests Possible Clinical Benefit in Early-Stage Parkinson's Disease
Negative
Zacks Investment Research
1 week ago
Why Is Prothena (PRTA) Down 17.9% Since Last Earnings Report?
Prothena (PRTA) reported earnings 30 days ago. What's next for the stock?
Why Is Prothena (PRTA) Down 17.9% Since Last Earnings Report?
Positive
Zacks Investment Research
1 month ago
Prothena Q3 Earnings Beat Estimates, Pipeline Progress in Focus
PRTA posts a narrower-than-expected loss in the third quarter. The company also reports encouraging pipeline progress for the quarter.
Prothena Q3 Earnings Beat Estimates, Pipeline Progress in Focus
Negative
Zacks Investment Research
1 month ago
Prothena (PRTA) Reports Q3 Loss, Misses Revenue Estimates
Prothena (PRTA) came out with a quarterly loss of $1.10 per share versus the Zacks Consensus Estimate of a loss of $1.18. This compares to earnings of $0.38 per share a year ago.
Prothena (PRTA) Reports Q3 Loss, Misses Revenue Estimates
Neutral
Business Wire
1 month ago
Prothena Reports Third Quarter 2024 Financial Results and Business Highlights
DUBLIN--(BUSINESS WIRE)---- $PRTA #prothena--Prothena today reported financial results for the third quarter and first nine months of 2024 and provided business highlights.
Prothena Reports Third Quarter 2024 Financial Results and Business Highlights
Positive
Zacks Investment Research
1 month ago
Will These 5 Biotech Stocks Surpass Q3 Earnings Forecasts?
Let's look at five biotech and drug companies, AZN, NVAX, AXSM, TBPH and PRTA, slated to release their third-quarter 2024 results this week.
Will These 5 Biotech Stocks Surpass Q3 Earnings Forecasts?
Neutral
Business Wire
1 month ago
Prothena to Report Third Quarter 2024 Financial Results on November 12
DUBLIN--(BUSINESS WIRE)---- $PRTA #prothena--Prothena today announced that it will report its third quarter and first nine months of 2024 financial results on Tuesday, November 12, 2024.
Prothena to Report Third Quarter 2024 Financial Results on November 12
Positive
Zacks Investment Research
1 month ago
Prothena (PRTA) Upgraded to Buy: What Does It Mean for the Stock?
Prothena (PRTA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Prothena (PRTA) Upgraded to Buy: What Does It Mean for the Stock?
Positive
Zacks Investment Research
1 month ago
Strength Seen in Prothena (PRTA): Can Its 15.0% Jump Turn into More Strength?
Prothena (PRTA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Strength Seen in Prothena (PRTA): Can Its 15.0% Jump Turn into More Strength?
Charts implemented using Lightweight Charts™